Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a study of ETX-155 in patients with hormone-related depressive disorders

Next Previous
Trial Profile

A phase 2a study of ETX-155 in patients with hormone-related depressive disorders

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ETX-155 (Primary)
  • Indications Depressive disorders
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 09 Feb 2023 According to an Eliem Therapeutics media release, the Company will pause all further development of ETX-155, that is Phase 2-ready for major depressive disorder (MDD), with the potential to also pursue development in epilepsy. The Board determined that, given current capital market conditions and investor sentiment around the GABAA PAM opportunity in MDD, it is not in the best interests of the Company or its stockholders to invest in the Phase 2a MDD trial at this time..
  • 09 Feb 2023 Status changed from planning to suspended, according to an Eliem Therapeutics media release.
  • 16 May 2022 According to an Eliem Therapeutics media release, the Company is in the process of investigating the root cause of the reduced exposure in phase 1 study and has elected to delay enrollment of the Phase 2a MDD and PMD trials pending further information from this root cause investigation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top